UK markets open in 4 hours 31 minutes

WuXi Biologics (Cayman) Inc. (2269.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
49.950+1.650 (+3.42%)
As of 10:14AM HKT. Market open.
Currency in HKD

Valuation measures4

Market cap (intra-day) 202.09B
Enterprise value 196.07B
Trailing P/E 46.82
Forward P/E 25.91
PEG ratio (5-yr expected) 0.69
Price/sales (ttm)14.67
Price/book (mrq)5.39
Enterprise value/revenue 14.98
Enterprise value/EBITDA 39.97

Trading information

Stock price history

Beta (5Y monthly) 0.89
52-week change 3-58.22%
S&P500 52-week change 3-13.12%
52-week high 3121.500
52-week low 340.300
50-day moving average 364.195
200-day moving average 367.513

Share statistics

Avg vol (3-month) 321.32M
Avg vol (10-day) 320.81M
Shares outstanding 54.26B
Implied shares outstanding 6N/A
Float 83.54B
% held by insiders 115.44%
% held by institutions 147.70%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 23:1
Last split date 316 Nov 2020

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Jun 2022

Profitability

Profit margin 31.18%
Operating margin (ttm)30.66%

Management effectiveness

Return on assets (ttm)5.51%
Return on equity (ttm)12.30%

Income statement

Revenue (ttm)13.09B
Revenue per share (ttm)3.13
Quarterly revenue growth (yoy)63.50%
Gross profit (ttm)4.83B
EBITDA 4.6B
Net income avi to common (ttm)4.08B
Diluted EPS (ttm)1.040
Quarterly earnings growth (yoy)37.60%

Balance sheet

Total cash (mrq)9.86B
Total cash per share (mrq)2.36
Total debt (mrq)4.4B
Total debt/equity (mrq)12.40
Current ratio (mrq)2.30
Book value per share (mrq)8.25

Cash flow statement

Operating cash flow (ttm)4.09B
Levered free cash flow (ttm)-1.32B